Celgene to obtain Pharmion for $2 cialisinorge.com/cialis-professional.html .9 Billion in Stock and Cash Celgene Corporation and Pharmion Company jointly announced the signing of a definitive merger agreement pursuant to which Celgene has agreed to acquire Pharmion. Under the conditions of the merger contract, Celgene will acquire all the outstanding shares of Pharmion common share for $72.00 per share payable in a combination of shares and cash of Celgene common stock. The transaction is expected to be somewhat dilutive to income in 2008 and accretive in 2009 2009 and beyond.
A Prescription Drug User Charge Act date will be founded by the FDA relating to the review of the pixantrone NDA by September 4th 2009. The FDA’s acceptance to document our pixantrone NDA represents a significant milestone for CTI and for sufferers with relapsed and refractory aggressive NHL. We anticipate working with the FDA and their ultimate decision on our request for priority review, noted James Bianco, M.D., CEO of CTI.. Cell Therapeutics’ NDA for Pixantrone accepted by the FDA Cell Therapeutics, Inc. announced today that the U.S. Food and Medication Administration has recognized and has filed for review the Company’s New Drug Application for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin’s lymphoma .